Treatment‐free remission in nontransplanted patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia
The current findings suggest that TKI discontinuation may be safe for highly selected patients with Ph-positive ALL in first complete remission who maintain CMR for at least 48 months. Larger studies are needed to confirm these findings.
Authors
- Farhad Ravandi (ORCID: https://orcid.org/0000-0002-7621-377X)
- Fadi Haddad (ORCID: https://orcid.org/0000-0002-9702-8485)
- Tapan Mahendra Kadia (ORCID: https://orcid.org/0000-0002-9892-9832)
- Nitin Jain (ORCID: https://orcid.org/0000-0003-0114-8384)
- Koji Sasaki (ORCID: https://orcid.org/0000-0002-9140-0610)
- Rebecca Garris
- Elias Joseph Jabbour (ORCID: https://orcid.org/0000-0003-4465-6119)
- Rashmi Kanagal‐Shamanna (ORCID: https://orcid.org/0000-0001-7829-5249)
- Hagop M. Kantarjian (ORCID: https://orcid.org/0000-0002-1908-3307)
- Nicholas James Short (ORCID: https://orcid.org/0000-0002-2983-2738)
- Eitan Kugler (ORCID: https://orcid.org/0009-0005-1539-1766)
- Niranjan Khaire
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1002/cncr.35773
- Citations
- 11
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 19.47